文献情報
- トップページ >
- 文献情報
NEW
Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan
Dermatol Ther(Heidelb).2023 May;13(5):1113-1126.
PubMed
Dermatol Ther(Heidelb).2023 May;13(5):1113-1126.
![メール](/assets/images/mail.png)
Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database
Orphanet J Rare Dis. 2022 Sep 14;17(1):355.
PubMed
Orphanet J Rare Dis. 2022 Sep 14;17(1):355.
![メール](/assets/images/mail.png)
Impact of facial angiofibromas in tuberous sclerosis complex and reported efficacy of available treatments
Front Med (Lausanne). 2022 Aug 29;9:967971.
PubMed
Front Med (Lausanne). 2022 Aug 29;9:967971.
![メール](/assets/images/mail.png)
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
Hope Northrup, et al. Pediatr Neurol. 2021 Oct;123:50-66.
PubMed
Hope Northrup, et al. Pediatr Neurol. 2021 Oct;123:50-66.
![メール](/assets/images/mail.png)
Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence
Clara Cortell Fuster, et al. J Dermatolog Treat. 2021 Apr 6;1-7.
PubMed
Clara Cortell Fuster, et al. J Dermatolog Treat. 2021 Apr 6;1-7.
![メール](/assets/images/mail.png)
Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
Takashi Hatano, et al. Orphanet J Rare Dis. 2020 Jun 1;15(1):133.
PubMed
Takashi Hatano, et al. Orphanet J Rare Dis. 2020 Jun 1;15(1):133.
![メール](/assets/images/mail.png)
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial.
Wataya-Kaneda M, et al. Dermatol Ther (Heidelb). 2020 May 8.
PubMed
Wataya-Kaneda M, et al. Dermatol Ther (Heidelb). 2020 May 8.
![メール](/assets/images/mail.png)
Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex.
Okanishi T, et al. Front Med (Lausanne). 2020 Jan 22;7:1.
PubMed
Okanishi T, et al. Front Med (Lausanne). 2020 Jan 22;7:1.
![メール](/assets/images/mail.png)
Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2018; 154(7): 781-788
PubMed
Wataya-Kaneda M, et al. JAMA Dermatol. 2018; 154(7): 781-788
![メール](/assets/images/mail.png)
Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2017; 153(1): 39-48
PubMed
Wataya-Kaneda M, et al. JAMA Dermatol. 2017; 153(1): 39-48
![メール](/assets/images/mail.png)
Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M, et al. JAMA Dermatol. 2015; 151(7): 722-730
PubMed
Wataya-Kaneda M, et al. JAMA Dermatol. 2015; 151(7): 722-730
![メール](/assets/images/mail.png)
Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
Nathan N, et al. J Am Acad Dermatol. 2015; 73(5): 802-808
PubMed
Nathan N, et al. J Am Acad Dermatol. 2015; 73(5): 802-808
![メール](/assets/images/mail.png)
Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knopfel N, et al. Actas Dermosifiliogr. 2014; 105(8): 802-803
PubMed
Knopfel N, et al. Actas Dermosifiliogr. 2014; 105(8): 802-803
![メール](/assets/images/mail.png)
Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
Muzic JG, et al. JAMA Dermatol. 2014; 150(9): 1024-1025
PubMed
Muzic JG, et al. JAMA Dermatol. 2014; 150(9): 1024-1025
![メール](/assets/images/mail.png)
A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Wataya-Kaneda M, et al. Arch Dermatol. 2012; 148(1): 138-139
PubMed
Wataya-Kaneda M, et al. Arch Dermatol. 2012; 148(1): 138-139
![メール](/assets/images/mail.png)
Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H, et al. Ren Fail. 2010; 32(10): 1233-1236
PubMed
Micozkadioglu H, et al. Ren Fail. 2010; 32(10): 1233-1236
![メール](/assets/images/mail.png)
Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A, et al. Transplant Proc. 2009; 41(9): 3677-3682
PubMed
Tarasewicz A, et al. Transplant Proc. 2009; 41(9): 3677-3682
![メール](/assets/images/mail.png)
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
Rauktys A, et al. BMC Dermatol. 2008; 8 : 1.
PubMed
Rauktys A, et al. BMC Dermatol. 2008; 8 : 1.
![メール](/assets/images/mail.png)